CD274 and nasopharyngeal carcinoma: Treating NPC patients with PD-L1 blockade is an effective strategy (163, 164); however, the anti-PD1 monoclonal antibody induces an immune response in NPC patients but shows no substantial effect in reducing tumor burden (165).